Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety

  title={Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety},
  author={Simona Lattanzi and Francesco Brigo and Eugen Trinka and Fabrizio Vernieri and Tommaso Corradetti and Mauro Dobran and Mauro Silvestrini},
BackgroundNovel therapeutic options with improved efficacy and safety profiles are needed for the prophylaxis of migraine. In recent years, the inhibition of calcitonin gene-related peptide (CGRP) signaling has attracted growing interest in the pharmacological research on migraine. Erenumab is the first fully human monoclonal antibody directed against the CGRP receptor to be approved for use in migraineurs.ObjectiveTo evaluate the efficacy and safety of erenumab as preventive treatment in… 

Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety

Atogepant is an efficacious and overall well-tolerated treatment for the prevention of episodic migraine in adults and there were no differences in the occurrence of AEs and drug withdrawal due to AEs between atogePant and placebo groups.

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials

Atogepant has shown good efficacy and safety in the prophylactic treatment of migraine, and further studies are expected.

Different Doses of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Network Meta-Analysis

Overall safety and efficacy and dose-response relationship of erenumab in patients with episodic migraine and patients with prior migraine treatment failures was evaluated and it was found that 140 mg erenUMab was associated with better efficacy outcomes without increased risk for developing adverse events.

Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons

The results from this study suggested erenumab 140 mg might provide better efficacy than 70 mg among adult patients with migraine, without increasing TEAEs.

The role of erenumab in the treatment of migraine

Clinical trials data suggest superiority of the CGRP mAbs to placebo to placebo in terms of prevention of migraine symptoms, migraine-specific quality of life and headache related disability.

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

The current body of evidence reveals that CGRP mAb is an effective and safe preventive treatment for episodic migraine.

Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative meta-analysis

Levetiracetam may be a relatively safe and efficacious treatment for the prophylaxis of migraine based on limited evidence, most from uncontrolled studies, but further evidence from randomized controlled trials is necessary.

Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine

With the CGRP antibodies, a group of drugs has entered the market which will most likely not only significantly improve the quality of life of many individual migraine patients but could also reduce indirect health-care costs associated with migraine by reducing recurrent medical consultations.

Recent Advances in Pharmacotherapy for Episodic Migraine

Episodic migraine treatment is reviewed and, as experience with monoclonal antibodies grows in clinical practice, an evolution in migraine management can be expected to take shape.

Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis

The safety profile is in favor of the CGRP(R) mAbs, with a higher likelihood to help than to harm compared with topiramate, with the diversity of endpoint determination and the heterogeneity between studies for some endpoints cause some limitations for this study.



The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis

Based on the results of this meta-analysis, CGRP monoclonal antibodies significantly reduced the monthly migraine days and acute migraine-specific medication and were effective and safe for preventive treatment of episodic migraine.

Early onset of efficacy with erenumab in patients with episodic and chronic migraine

There was evidence of onset of efficacy of erenumab vs. placebo during the first week of treatment, which in some cases reached nominal significance, in both episodic migraine patients.

A Controlled Trial of Erenumab for Episodic Migraine

Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine–specific medication over a period of 6 months.

Erenumab in the treatment of migraine.

This review will focus on the first US FDA-approved CGRP-receptor monoclonal antibody developed for the prevention of migraine: erenumab.

Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab

Erenumab reduced migraine disability and impact and improved patients’ health-related quality of life, reinforcing its role as a promising new therapy for migraine prevention.

Topiramate in migraine prevention: results of a large controlled trial.

Topiramate, 100 or 200 mg/d, was effective as a preventive therapy for patients with migraine and eliminated paresthesia, fatigue, nausea, anorexia, and taste per version.

Drug safety and tolerability in prophylactic migraine treatment

The background of the recurrence and chronification of migraine attacks has not been fully clarified, and causative preventive therapy is therefore not currently available, and the tolerability and adverse effects of the currently used medications often limit their use.

Topiramate for migraine prevention: a randomized controlled trial.

Topiramate showed significant efficacy in migraine prevention within the first month of treatment, an effect maintained for the duration of the double-blind phase.